Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorEastwood, Glenn Men
dc.contributor.authorLitton, Eden
dc.contributor.authorBellomo, Rinaldoen
dc.contributor.authorBailey, Michael Jen
dc.contributor.authorFesta, Marioen
dc.contributor.authorBeasley, Richard Wen
dc.contributor.authorYoung, Paul Jen
dc.identifier.citationCritical Care and Resuscitation; 16(3): 170-4en
dc.description.abstractIntensivists frequently prescribe proton pump inhibitors (PPIs) or histamine-2 receptor blockers (H2RBs) to intensive care unit patients for stress ulcer prophylaxis (SUP). Despite the common use of SUP medicines, there is limited high-level evidence to support the choice between them.To describe self-reported practice of SUP by Australian and New Zealand intensivists.An online questionnaire of intensivists between 13 January and 3 February 2014.Seventy-two intensivists responded to the survey: 61 (85%) practised in public metropolitan ICUs and 13/48 (27%) practised in paediatric ICUs. Fifty-two (72%) respondents indicated that PPIs were their preferred SUP medicine. Respondents estimated that an average of 84% of ventilated and 53% of non-ventilated patients received SUP medicines during their ICU admission. Seven respondents (9%) were concerned or very concerned about the possible increased risk of upper gastrointestinal bleeding associated with H2RBs versus PPIs. Ten respondents (14%) were concerned or very concerned about the possible greater risk of Clostridium difficile infection, and 15 respondents (21%) were concerned or very concerned about the possible greater risk or ventilator-associated pneumonia with PPIs versus H2RBs. Most respondents (64 [89%]) agreed or strongly agreed that there was insufficient evidence to support the choice of an optimal SUP medicine, and 58 respondents (81%) agreed or strongly agreed to patient enrollment in an RCT comparing PPIs with H2RBs.Most survey respondents felt that current evidence is insufficient to justify the preferential use of PPIs or H2RBs for SUP and would enroll patients in a comparative SUP RCT.en
dc.subject.otherAttitude of Health Personnelen
dc.subject.otherClostridium difficileen
dc.subject.otherData Collectionen
dc.subject.otherEnterocolitis, Pseudomembranous.chemically induceden
dc.subject.otherHistamine H2 Antagonists.adverse effects.therapeutic useen
dc.subject.otherIntensive Careen
dc.subject.otherNew Zealanden
dc.subject.otherPeptic Ulcer.prevention & controlen
dc.subject.otherPneumonia, Ventilator-Associated.etiologyen
dc.subject.otherProton Pump Inhibitors.adverse effects.therapeutic useen
dc.titleOpinions and practice of stress ulcer prophylaxis in Australian and New Zealand intensive care units.en
dc.typeJournal Articleen
dc.identifier.journaltitleCritical Care and Resuscitationen
dc.identifier.affiliationAustralian and New Zealand Intensive Care Research Centre, Department of Epidemiology and Preventive Medicine, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Intensive Care, The Children's Hospital at Westmead, Sydney, NSW, Australiaen
dc.identifier.affiliationDepartment of Intensive Care, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Intensive Care, Royal Perth Hospital, Perth, WA, Australiaen
dc.identifier.affiliationMedical Research Institute of New Zealand, Wellington, New Zealand.en
dc.type.austinJournal Articleen
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.languageiso639-1en- Care- Care- Analytics Research and Evaluation (DARE) Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jan 31, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.